NCT07217860View on ClinicalTrials.gov

An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

August 31, 2029

Conditions
Bipolar DepressionBipolar I DisorderBipolar DisorderBipolar II Disorder
Interventions
DRUG

Azetukalner

Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 52 weeks.

Trial Locations (2)

32801

Clinical Neuroscience Solutions, Orlando

38119

Clinical Neuroscience Solutions Memphis, Memphis

All Listed Sponsors
lead

Xenon Pharmaceuticals Inc.

INDUSTRY